{"title":"Identifying Basement Membrane-Related Diagnostic Biomarkers for Rheumatoid Arthritis Through Machine Learning.","authors":"Lingtian Min, Chengji Zhang, Long Xu, Jielin Deng, Haihu Wang, Shiqi Ren, Cheng Chen","doi":"10.2174/0115665232468196260521104934","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Rheumatoid Arthritis (RA) is a common autoimmune disease. The Basement Membrane (BM) plays a critical structural role in tissues such as the kidneys and joints, and is often implicated in immune-related diseases. This study aims to explore the complex interactions between RA and the BM, and to identify potential diagnostic biomarkers.</p><p><strong>Methods: </strong>The data used in this study were sourced from the Gene Expression Omnibus (GEO) database. We screened Differentially Expressed Genes (DEGs) related to BM by comparing RA tissue with normal tissue. Consensus clustering analysis was performed based on the features of the BM in RA tissue samples. Functional enrichment analyses, including Gene Ontology (GO) and KEGG pathway analysis, were performed on genes common to the different clusters. Three machine learning algorithms were used to screen for biomarkers, including LASSO, Random Forest (RF), and Support Vector Machine Recursive Feature Elimination (SVM-RFE). The screening results were validated using the GSE77298 dataset and confirmed via qRT-PCR. In addition, molecular docking technology was applied to predict the binding potential between Schisandrin (SCH) and the candidate biomarkers SEL1L3 and SLAMF8.</p><p><strong>Results: </strong>By integrating RA transcriptome data with BM-related genes, we identified two BMassociated molecular subtypes of RA, both of which exhibit distinct immune cell infiltration characteristics. By further implementing a combination of LASSO, RF, and SVM-RFE, SEL1L3 and SLAMF8 were identified as candidate diagnostic biomarkers. In the external validation set (GSE77298) and qRT-PCR experiments, both exhibited significant upregulation in RA tissue and excellent diagnostic efficacy. The AUC of SEL1L3 and SLAMF8 was 0.987 and 0.970, respectively, and molecular docking suggests that SCH binds stably to both.</p><p><strong>Discussion: </strong>The research results indicate that molecular changes related to BM may play an important role in the pathogenesis of RA, particularly through immune regulation and tissue remodeling. Identifying different subtypes of BM-related RA highlights the heterogeneity of RA and may help improve disease classification and personalized diagnosis. SEL1L3 and SLAMF8 can serve as promising biomarkers for early RA detection and provide new insights into BM-related immune mechanisms.</p><p><strong>Conclusion: </strong>SEL1L3 and SLAMF8 are the first BM-associated RA diagnostic markers identified, providing new targets for early RA diagnosis and investigation of its molecular mechanisms.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232468196260521104934","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Rheumatoid Arthritis (RA) is a common autoimmune disease. The Basement Membrane (BM) plays a critical structural role in tissues such as the kidneys and joints, and is often implicated in immune-related diseases. This study aims to explore the complex interactions between RA and the BM, and to identify potential diagnostic biomarkers.
Methods: The data used in this study were sourced from the Gene Expression Omnibus (GEO) database. We screened Differentially Expressed Genes (DEGs) related to BM by comparing RA tissue with normal tissue. Consensus clustering analysis was performed based on the features of the BM in RA tissue samples. Functional enrichment analyses, including Gene Ontology (GO) and KEGG pathway analysis, were performed on genes common to the different clusters. Three machine learning algorithms were used to screen for biomarkers, including LASSO, Random Forest (RF), and Support Vector Machine Recursive Feature Elimination (SVM-RFE). The screening results were validated using the GSE77298 dataset and confirmed via qRT-PCR. In addition, molecular docking technology was applied to predict the binding potential between Schisandrin (SCH) and the candidate biomarkers SEL1L3 and SLAMF8.
Results: By integrating RA transcriptome data with BM-related genes, we identified two BMassociated molecular subtypes of RA, both of which exhibit distinct immune cell infiltration characteristics. By further implementing a combination of LASSO, RF, and SVM-RFE, SEL1L3 and SLAMF8 were identified as candidate diagnostic biomarkers. In the external validation set (GSE77298) and qRT-PCR experiments, both exhibited significant upregulation in RA tissue and excellent diagnostic efficacy. The AUC of SEL1L3 and SLAMF8 was 0.987 and 0.970, respectively, and molecular docking suggests that SCH binds stably to both.
Discussion: The research results indicate that molecular changes related to BM may play an important role in the pathogenesis of RA, particularly through immune regulation and tissue remodeling. Identifying different subtypes of BM-related RA highlights the heterogeneity of RA and may help improve disease classification and personalized diagnosis. SEL1L3 and SLAMF8 can serve as promising biomarkers for early RA detection and provide new insights into BM-related immune mechanisms.
Conclusion: SEL1L3 and SLAMF8 are the first BM-associated RA diagnostic markers identified, providing new targets for early RA diagnosis and investigation of its molecular mechanisms.
期刊介绍:
Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases.
Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.